There is substantial research on the vasoactive peptide endothelin (ET)-1 in physiology, as
well as in pathology. In fact, pathologically elevated levels of ET-1 have been found in …

Objectives. Although many studies have reported on the cost‐effectiveness of bosentan for
treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations …

Macitentan is a safe and effective substance for treatment of adults with pulmonary arterial
hypertension. Data on its use in paediatric patients are limited. In this single-centre …

High blood pressure in the portal vein, portal hypertension (PH), is the final common
pathway in liver cirrhosis regardless of aetiology. Complications from PH are the major …

Several endothelin receptor antagonists (ERAs) have been developed for the treatment of
pulmonary arterial hypertension (PAH). Some of them have been related to clinical cases of …

Macitentan is a medication in the endothelin receptor antagonist class, approved for
treatment of pulmonary arterial hypertension in 2013 based on the results of the pivotal …

The Sugen 5416/hypoxia (Su/Hx) rat model of pulmonary arterial hypertension (PAH)
demonstrates most of the distinguishing features of PAH in humans, including increased …

Background Macitentan is the latest endothelin-receptor antagonist (ERA) approved for the
treatment of pulmonary arterial hypertension (PAH), presenting enhanced properties over …

Abstract Background Persistent Pulmonary Hypertension of the newborn (PPHN) is
characterized by sustained elevated Pulmonary Artery Pressure (PAP). Drug resistance and …

Ubiquitously expressed β-arrestin1 (β-arr1) and β-arrestin2 (β-arr2) proteins were originally
identified and characterized based on their function to desensitize activated G protein …